The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production

Biochemical and Biophysical Research Communications

Volumn 463, Issue 4, 2015, Pages 545-550

  Xu, Weihong ^a   Xu, Bin ^a   Yao, Yiting ^a   Yu, Xiaoling ^a   Shen, Jie ^a  

^a Shanghai Jiao Tong University School of Medicine   (China)

Author keywords

AR 42 and ceramide and apoptosis; Colon cancer; HDAC inhibitor

Indexed keywords

AR 42; CERAMIDE; HISTONE DEACETYLASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; ARYLBUTYRIC ACID DERIVATIVE; OSU-HDAC42 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BIOSYNTHESIS; COLONIC NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; SCID MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CERAMIDES; COLONIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE; MICE, SCID; PHENYLBUTYRATES;

EID: 84936891712     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.05.078     Document Type: Article

References (27)

1. J.M. Hubbard, and A. Grothey Colorectal cancer in 2014: progress in defining first-line and maintenance therapies Nat. Rev. Clin. Oncol. 12 2015 73 74
2. H.J. Schmoll, and A. Stein Colorectal cancer in 2013: towards improved drugs, combinations and patient selection Nat. Rev. Clin. Oncol. 11 2014 79 80
3. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
4. D.M. Gustin, and D.E. Brenner Chemoprevention of colon cancer: current status and future prospects Cancer Metastasis Rev. 21 2002 323 348
5. I. Chau, and D. Cunningham Adjuvant therapy in colon cancer: current status and future directions Cancer Treat. Rev. 28 2002 223 236
6. K.J. Falkenberg, and R.W. Johnstone Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders Nat. Rev. Drug Discov. 13 2014 673 691
7. J.W. Hojfeldt, K. Agger, and K. Helin Histone lysine demethylases as targets for anticancer therapy Nat. Rev. Drug Discov. 12 2013 917 930
8. J.M. Mariadason HDACs and HDAC inhibitors in colon cancer Epigenetics 3 2008 28 37
9. D.R. Li, H. Zhang, E. Peek, S. Wang, L. Du, G. Li, and A.I. Chin Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer J. Urol. 2015 (Epub ahead of print)
10. M.L. Guzman, N. Yang, K.K. Sharma, M. Balys, C.A. Corbett, C.T. Jordan, M.W. Becker, U. Steidl, O. Abdel-Wahab, R.L. Levine, G. Marcucci, G.J. Roboz, and D.C. Hassane Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia Mol. Cancer Ther. 13 2014 1979 1990
11. S.S. Burns, E.M. Akhmametyeva, J.L. Oblinger, M.L. Bush, J. Huang, V. Senner, C.S. Chen, A. Jacob, D.B. Welling, and L.S. Chang Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth Cancer Res. 73 2013 792 803
12. T.Y. Lin, J. Fenger, S. Murahari, M.D. Bear, S.K. Kulp, D. Wang, C.S. Chen, W.C. Kisseberth, and C.A. London AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit Blood 115 2010 4217 4225
13. B. Ogretmen, and Y.A. Hannun Biologically active sphingolipids in cancer pathogenesis and treatment Nat. Rev. Cancer 4 2004 604 616
14. S. Mathias, L.A. Pena, and R.N. Kolesnick Signal transduction of stress via ceramide Biochem. J. 335 Pt 3 1998 465 480
15. C. Li, J.F. Cui, M.B. Chen, C.Y. Liu, F. Liu, Q.D. Zhang, J. Zou, and P.H. Lu The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent Cancer Biol. Ther. 16 2015 34 42
16. J. Kizhakkayil, F. Thayyullathil, S. Chathoth, A. Hago, M. Patel, and S. Galadari Glutathione regulates caspase-dependent ceramide production and curcumin-induced apoptosis in human leukemic cells Free Radic. Biol. Med. 52 2012 1854 1864
17. N.J. Pyne, and S. Pyne Sphingosine 1-phosphate and cancer Nat. Rev. Cancer 10 2010 489 503
18. A. Shukla, and N.S. Radin Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase J. Lipid Res. 32 1991 713 722
19. A.H. Merrill Jr., G. van Echten, E. Wang, and K. Sandhoff Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ J. Biol. Chem. 268 1993 27299 27306
20. R.J. Veldman, K. Klappe, D. Hoekstra, and J.W. Kok Metabolism and apoptotic properties of elevated ceramide in HT29rev cells Biochem. J. 331 Pt 2 1998 563 569
21. T. Babia, R.J. Veldman, D. Hoekstra, and J.W. Kok Modulation of carcinoembryonic antigen release by glucosylceramide-implications for HT29 cell differentiation Eur. J. Biochem. 258 1998 233 242
22. R. Bose, M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z. Fuks, and R. Kolesnick Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals Cell 82 1995 405 414
23. J.P. Jaffrezou, T. Levade, A. Bettaieb, N. Andrieu, C. Bezombes, N. Maestre, S. Vermeersch, A. Rousse, and G. Laurent Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis Embo J. 15 1996 2417 2424
24. D. Myrick, D. Blackinton, J. Klostergaard, N. Kouttab, A. Maizel, H. Wanebo, and S. Mehta Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide Leuk. Res. 23 1999 569 578
25. T. Yu, J. Li, Y. Qiu, and H. Sun 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation Mol. Cell. Biochem. 361 2011 47 54
26. A.J. Dijkhuis, K. Klappe, S. Jacobs, B.J. Kroesen, W. Kamps, H. Sietsma, and J.W. Kok PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy Mol. Cancer Ther. 5 2006 593 601
27. H. Sietsma, R.J. Veldman, D. Kolk, B. Ausema, W. Nijhof, W. Kamps, E. Vellenga, and J.W. Kok 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine Clin. Cancer Res. 6 2000 942 948